Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review

No abstract is available for this paper.

• Publication year

  2013

• Venue

  European Child and Adolescent Psychiatry

• Publication date

  2013-03-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00787-013-0399-5PMID 23503976
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differences in Body Mass Index z-Scores and Weight Status in a Dutch Pediatric Psychiatric Population With and Without Use of Second-Generation Antipsychotics

  2012cited by this paper
• A prospective open-label trial of quetiapine monotherapy in preschool and school age children with bipolar spectrum disorder.

  2012cited by this paper
• Comparison of Long-Term (At Least 24 Weeks) Weight Gain and Metabolic Changes Between Adolescents and Adults Treated with Olanzapine

  2012cited by this paper
• A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents.

  2012cited by this paper
• Adverse Effects of Second-Generation Antipsychotics in Children and Adolescents: A Bayesian Meta-Analysis

  2012cited by this paper
• Overweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample.

  2012cited by this paper
• Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain.

  2012cited by this paper
• Aripiprazole in pediatric psychosis and bipolar disorder: a clinical review.

  2012cited by this paper
• Subjective and biological weight-related parameters in adolescents and young adults with schizophrenia spectrum disorder under clozapine or olanzapine treatment.

  2012cited by this paper
• [The metabolic syndrome and antipsychotics in children and adolescents].

  2011cited by this paper
• An Open-Label Study of Aripiprazole in Children with a Bipolar Disorder

  2011cited by this paper
• Review on the current use of antipsychotic drugs in children and adolescents

  2011cited by this paper
• Metabolic and Neurological Complications of Second-Generation Antipsychotic Use in Children

  2011cited by this paper
• Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old):results from a pooled analysis of 2 studies.

  2011cited by this paper
• Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents

  2011cited by this paper
• Predictors of Risperidone and 9-Hydroxyrisperidone Serum Concentration in Children and Adolescents

  2011cited by this paper
• Weight Gain and Metabolic Syndrome Among Young Patients on Antipsychotic Medication: What do we Know and Where do we go?

  2011cited by this paper
• Stress and Affective Disorders: Animal Models Elucidating the Molecular Basis of Neuroendocrine-Behavior Interactions

  2011cited by this paper
• Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis

  2011cited by this paper
• Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.

  2011cited by this paper
• Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents

  2011cited by this paper
• Addressing adverse effects of antipsychotic treatment in young patients with schizophrenia.

  2011cited by this paper
• Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study.

  2011cited by this paper
• Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

  2011cited by this paper
• Body weight gain induced by atypical antipsychotics: an extension of the monocygotic twin and sib pair study

  2010cited by this paper
• Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.

  2010cited by this paper
• [Metabolic side effects of risperidone in early onset schizophrenia].

  2010cited by this paper
• A PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FLEXIBLY DOSED ORAL ZIPRASIDONE IN ADOLESCENT SUBJECTS WITH SCHIZOPHRENIA

  2010cited by this paper
• Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.

  2010cited by this paper
• Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials.

  2010cited by this paper
• Effectiveness and Tolerability of Aripiprazole in Children and Adolescents with Tourette's Disorder: A Pilot Study in China

  2010cited by this paper
• A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents

  2010cited by this paper
• Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions

  2010cited by this paper
• Moderators, Mediators, and Other Predictors of Risperidone Response in Children with Autistic Disorder and Irritability

  2010cited by this paper
• Association Study of Energy Homeostasis Genes and Antipsychotic-Induced Weight Gain in Patients with Schizophrenia

  2010cited by this paper
• Risperidone-Induced Weight Gain in Referred Children with Autism Spectrum Disorders Is Associated with a Common Polymorphism in the 5-Hydroxytryptamine 2C Receptor Gene

  2010cited by this paper
• Depressive symptoms and the metabolic syndrome in childhood and adulthood: a prospective cohort study.

  2009cited by this paper
• Olanzapine compared to quetiapine in adolescents with a first psychotic episode

  2009cited by this paper
• Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.

  2009cited by this paper
• Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder

  2009cited by this paper
• Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course.

  2009cited by this paper
• Weight Gain and Metabolic Abnormalities During Extended Risperidone Treatment in Children and Adolescents

  2009cited by this paper
• The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials.

  2009cited by this paper
• Increased Prevalence of Obesity and Glucose Intolerance in Youth Treated with Second—Generation Antipsychotic Medications

  2009cited by this paper
• Comparison of Open-Label, 8-Week Trials of Olanzapine Monotherapy and Topiramate Augmentation of Olanzapine for the Treatment of Pediatric Bipolar Disorder

  2009cited by this paper
• Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia.

  2009cited by this paper
• A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study.

  2009cited by this paper
• Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study.

  2009cited by this paper
• Leptin Gene –2548G/A variants predict risperidone-associated weight gain in children and adolescents

  2009cited by this paper
• Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.

  2009cited by this paper
• The Use of Second-Generation Antipsychotics and the Changes in Physical Growth in Children and Adolescents with Perinatally Acquired HIV

  2009cited by this paper
• A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder.

  2009cited by this paper
• Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study.

  2009cited by this paper
• Body mass index changes and chronic neuroleptic drug treatment for Tourette syndrome.

  2009cited by this paper
• Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study.

  2009cited by this paper
• Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial.

  2009cited by this paper
• Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study.

  2009cited by this paper
• Effects of Olanzapine and Risperidone on Metabolic Factors in Children and Adolescents: A Retrospective Evaluation

  2009cited by this paper
• Treating Disruptive Behavior Disorders with Risperidone: A 1-Year, Open-Label Safety Study in Children and Adolescents

  2008cited by this paper
• Adverse events in children and adolescents treated with antipsychotic medications

  2008cited by this paper
• Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone

  2008cited by this paper
• Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.

  2008cited by this paper
• Preliminary findings regarding overweight and obesity in pediatric bipolar disorder.

  2008cited by this paper
• Tolerability of Oral Ziprasidone in Children and Adolescents with Bipolar Mania, Schizophrenia, or Schizoaffective Disorder

  2008cited by this paper
• Large Intraindividual Variability of Olanzapine Serum Concentrations in Adolescent Patients

  2008cited by this paper
• Effectiveness and Tolerability of Olanzapine in the Treatment of Adolescents with Schizophrenia and Related Psychotic Disorders: Results from a Large, Prospective, Open-Label Study

  2008cited by this paper
• Large Variability of Aripiprazole and Dehydroaripiprazole Serum Concentrations in Adolescent Patients with Schizophrenia

  2008cited by this paper
• Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison.

  2008cited by this paper
• A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.

  2008cited by this paper
• Effectiveness and Tolerability of Open Label Olanzapine in Children and Adolescents with Tourette Syndrome

  2008cited by this paper
• Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.

  2008cited by this paper
• Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.

  2008cited by this paper
• A Comparative Pilot Study of Second-Generation Antipsychotics in Children and Adolescents with Schizophrenia-Spectrum Disorders

  2008cited by this paper
• A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents.

  2008cited by this paper
• Schizophrenia, Obesity, and Antipsychotic Medications: What Can We Do?

  2008cited by this paper
• Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder

  2008cited by this paper
• Antipsychotic Treatment in Child and Adolescent First-Episode Psychosis: A Longitudinal Naturalistic Approach

  2008cited by this paper
• Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.

  2008cited by this paper
• Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents

  2007cited by this paper
• A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder.

  2007cited by this paper
• Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients

  2007cited by this paper
• Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets

  2007cited by this paper
• A Prospective 12-Week Study of Quetiapine in Adolescents with Schizophrenia Spectrum Disorders

  2007cited by this paper
• An Open-Label Study of Olanzapine in Children and Adolescents with Schizophrenia

  2007cited by this paper
• Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials.

  2007cited by this paper
• Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study.

  2007cited by this paper
• Body Mass Indexes and Lipid Profiles in Hospitalized Children and Adolescents Exposed to Atypical Antipsychotics

  2007cited by this paper
• The public health aspects of bipolar disorder in children and adolescents

  2007cited by this paper
• A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder.

  2007cited by this paper
• An Open-Label Trial of Aripiprazole Monotherapy in Children and Adolescents with Bipolar Disorder

  2007cited by this paper
• [Prescription of olanzapine in children and adolescent psychiatric patients].

  2007cited by this paper
• Prescription de l’olanzapine chez l’enfant et l’adolescent

  2007cited by this paper
• An Open-Label Randomized Comparison of Olanzapine Versus Risperidone in the Treatment of Childhood-Onset Schizophrenia

  2006cited by this paper
• Clinical Drug Monitoring in Child and Adolescent Psychiatry: Side Effects of Atypical Neuroleptics

  2006cited by this paper
• A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania.

  2006cited by this paper
• Risperidone in Children With Autism: Randomized, Placebo-Controlled, Double-Blind Study

  2006cited by this paper
• Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders

  2006cited by this paper
• Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.

  2006cited by this paper
• Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents.

  2006cited by this paper
• Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study.

  2006cited by this paper

• Alterations of appetite‐regulating hormones in risperidone treated children and adolescents—a post hoc analysis of the SPACe study

  2025cites this paper
• Drugs used in psychiatry causing an increase in body weight in children—a review

  2024cites this paper
• Development and Evaluation of the “Eating More Consciously” Module of a Lifestyle Intervention Program to Prevent Medication-Induced Weight Gain in Psychiatric Patients: A One-Arm Pilot Study

  2024cites this paper
• Exercise and Pharmacotherapy for the Treatment of Eating Disorders: A Meta-Analysis

  2023cites this paper
• A Double-Blind Placebo-Controlled Pilot Study of Topiramate in Manic Adolescents Treated with Olanzapine

  2023cites this paper
• Gut microbiome profiles may be related to atypical antipsychotic associated overweight in Asian children with psychiatric disorder: a preliminary study

  2023cites this paper
• Polypharmacy in children and adolescents initiating antipsychotic drug in 2008–2016: a nationwide register study

  2022cites this paper
• Fourteen‐year trends in the prescribing patterns of pediatric bipolar patients discharged from two public mental hospitals in Taiwan

  2022cites this paper
• Obesity II: Establishing Causal Links Between Chemical Exposures and Obesity.

  2022cites this paper
• CYP2D6 Genetic Variation and Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis

  2022cites this paper
• The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children

  2021cites this paper
• Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression.

  2021cites this paper
• Effect of an online healthy lifestyle psychoeducation programme to improve cardiometabolic outcomes and affective symptoms in youth receiving mental health care: study protocol for a pilot clinical trial.

  2021cites this paper
• Body mass index increase in preschoolers with heterogeneous psychiatric diagnoses treated with risperidone

  2021cites this paper
• Interventions to Improve Metabolic Risk Screening Among Children and Adolescents on Antipsychotic Medication: A Systematic Review

  2021cites this paper
• Monitoring of metabolic adverse events of second-generation antipsychotics in a naive paediatric population followed in mental health outpatient and inpatient clinical settings: MEMAS prospective study protocol

  2021cites this paper
• Analysis of the status of drug treatment in 746 inpatients with early-onset schizophrenia in China: a retrospective study

  2021cites this paper
• The Importance of Second-Generation Antipsychotic-Related Weight Gain and Adherence Barriers in Youth with Bipolar Disorders: Patient, Parent, and Provider Perspectives

  2020cites this paper
• Effects of Steps to Success Exercise Program in Weight Management For Psychiatric Patients Taking Atypical Antipsychotic Drugs

  2020cites this paper
• Steps To Success Exercise Program In Weight Management For Psychiatric Patients Taking Atypical Antipsychotic Drugs

  2020cites this paper
• Current follow‐up practices often fail to detect metabolic and neurological adverse reactions in children treated with second‐generation antipsychotics

  2019cites this paper
• Monitoring of drug misuse or potential misuse in a nationwide healthcare insurance database: A cross-sectional study in France.

  2019cites this paper
• A prospective study of adverse effects of antipsychotics in adolescents with schizophrenia during a 6-month follow-up

  2019cites this paper
• The effects of antipsychotic medications on microbiome and weight gain in children and adolescents

  2019cites this paper
• Antipsychotic-induced weight gain and birth weight in psychosis: A fetal programming model.

  2019cites this paper
• Obesity in Adolescents with Psychiatric Disorders

  2019cites this paper
• Growth and weight status of Brazilian children with autism spectrum disorders: A mixed longitudinal study.

  2019cites this paper
• Aumento da Adiposidade em Adolescentes em Uso de Risperidona

  2019cites this paper
• Second generation antipsychotic-induced weight gain in youth with autism spectrum disorders: a brief review of mechanisms, monitoring practices, and indicated treatments

  2019cites this paper
• Early weight gain predicts later metabolic syndrome in depressed patients treated with antidepressants: Findings from the METADAP cohort.

  2018cites this paper
• Cardiovascular and metabolic monitoring of children and adolescents on antipsychotic treatment: A cross-sectional descriptive study.

  2018cites this paper
• One-Year Prospective Study of Liver Function Tests in Children and Adolescents on Second-Generation Antipsychotics: Is There a Link with Metabolic Syndrome?

  2018cites this paper
• Weight changes associated with antiepileptic mood stabilizers in the treatment of bipolar disorder

  2018cites this paper
• Double jeopardy: a review of weight gain and weight management strategies for psychotropic medication prescribing during methadone maintenance treatment

  2018cites this paper
• Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study

  2018influential citation
• Cardiovascular and metabolic side effects in patients using anti-depressants or antipsychotic medications. A mixed method systematic review

  2018cites this paper
• TOOLKIT TO IMPROVE PROVIDER ADHERENCE TO METABOLIC MONITORING OF ATYPICAL ANTIPSYCHOTICS FOR YOUTHS

  2018cites this paper
• Title: Cardiovascular and metabolic Side Effects in Patients Using Anti-depressants or Antipsychotic Medications: A Systematic Review Protocol

  2018cites this paper
• Pediatric Antipsychotic Use and Outcomes Monitoring

  2017cites this paper
• Commentary: A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated with Initiation of Atypical Antipsychotic Therapy in Children and Adolescents

  2017cites this paper
• The association of addictive-like eating with food intake in children.

  2017cites this paper
• Medical Conditions and Demographic, Service and Clinical Factors Associated with Atypical Antipsychotic Medication Use Among Children with An Autism Spectrum Disorder

  2017cites this paper
• Treatment of Obesity Among Youth With Intellectual and Developmental Disabilities: An Emerging Role for Telenursing

  2017cites this paper
• Clinical Factors Associated with Weight Gain in French-Canadian Children and Adolescents Treated With Second Generation Antipsychotics: A 24-Month Retrospective Study

  2017influential citation
• Genetic Correlation Profile of Schizophrenia Mirrors Epidemiological Results and Suggests Link Between Polygenic and Rare Variant (22q11.2) Cases of Schizophrenia

  2017cites this paper
• Long-Term Metabolic Effects in French-Canadian Children and Adolescents Treated with Second-Generation Antipsychotics in Monotherapy or Polytherapy: A 24-Month Descriptive Retrospective Study

  2017cites this paper
• Clinical use of second-generation antipsychotics in children

  2017cites this paper
• Neural changes induced by antipsychotic administration in adolescence: A review of studies in laboratory rodents

  2016cites this paper
• The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study

  2016influential citation
• Metformin as a Possible Intervention for Cardiometabolic Risks in Pediatric Subjects Exposed to Antipsychotic Drugs.

  2016cites this paper
• Association of the BDNF Val66Met polymorphism with BMI in chronic schizophrenic patients and healthy controls

  2016cites this paper
• Evaluating long-term consequences of adolescent antipsychotic exposure

  2016cites this paper
• Efficacy and safety of adjunctive topiramate for schizophrenia: a meta‐analysis of randomized controlled trials

  2016cites this paper
• Cardiovascular and metabolic monitoring of children and adolescents on antipsychotic treatment: A cross-sectional descriptive study.

  2016cites this paper
• Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials

  2015influential citation
• Atypical antipsychotics in the treatment of early-onset schizophrenia

  2015cites this paper
• Antipsychotic-induced metabolic effects in the female rat: Direct comparison between long-acting injections of risperidone and olanzapine

  2015cites this paper
• Chapter 6 - Antipsychotic Drugs

  2015cites this paper
• Strategies to implement physical health monitoring in people affected by severe mental illness : a literature review and introduction to the Italian adaptation of the Positive Cardiometabolic Health Algorithm

  2015cites this paper
• [Non-Pharmacological Interventions for the Prevention of Weight Gain in Schizophrenic Patients Treated with Antipsychotic Medication].

  2015cites this paper
• Explorations of the Use of Olanzapine for Management of Chemotherapy-induced Nausea and Vomiting in Children

  2015cites this paper
• Antipsychotic prescribing in youths: a French community-based study from 2006 to 2013

  2015cites this paper
• Weight gain and antipsychotics: a drug safety review

  2015cites this paper
• Risk Factors for Weight Gain and Metabolic Syndrome in Adolescents with Psychiatric Disorders: A Historical Prospective Study

  2015cites this paper
• Genetic Exploration of Valproate Induced Weight Gain

  2015cites this paper
• Atypical antipsychotics in the treatment of early-onset schizophrenia

  2015cites this paper
• Dietary energy intakes in children with mental health conditions treated with second‐generation antipsychotics (371.8)

  2014cites this paper
• Aumento de peso y de índice de masa corporal en niños y adolescentes tratados con antipsicóticos: revisión crítica y estudio longitudinal

  2014influential citation
• The Safety of Olanzapine in Young Children: A Systematic Review and Meta-Analysis

  2014cites this paper
• Metabolic Effects of Antipsychotics in Prepubertal Children: A Retrospective Chart Review

  2014cites this paper
• Metabolomic profiling of schizophrenia patients at risk for metabolic syndrome.

  2014cites this paper
• Improving Metabolic and Cardiovascular Health at an Early Psychosis Intervention Program in Vancouver, Canada

  2014cites this paper
• Factors Contributing to Weight Gain in Children Who Take Atypical Antipsychotics

  2014cites this paper
• Metabolomic pro fi ling of schizophrenia patients at risk for metabolic syndrome

  2014cites this paper
• A twenty-four-week, open-label study on ziprasidone's efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder.

  2013cites this paper
• Psychopharmacological treatment in children: always keeping an eye on adherence and ethics

  2013cites this paper
• Strategies for prevention and management of second generation antipsychotic-induced metabolic side effects

  2013cites this paper